Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIITerminatedOct 2, 2019ZarontinLabeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be...Pfizer Inc. · D-0002-2020Class IIITerminatedOct 2, 2019ethosuximide capsulesLabeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be...Pfizer Inc. · D-0001-2020Class IITerminatedSep 25, 2019AllergyFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1874-2019Class IITerminatedSep 25, 2019Wal-FexFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1873-2019Class IITerminatedSep 25, 2019AllergyFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1872-2019Class IITerminatedSep 25, 2019Fexofenadine HCL Tablets USPFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1871-2019Class IITerminatedSep 25, 2019Fexofenadine Hydrochloride Tablets USPFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1870-2019Class IITerminatedSep 25, 2019Allergy ReliefFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1869-2019Class IITerminatedSep 25, 2019Fexofenadine Hydrochloride Tablets USPFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1868-2019Class IITerminatedSep 25, 2019fexofenadine hydrochloride tablets USPFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1867-2019Class IITerminatedSep 25, 2019Allergy ReliefFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1866-2019Class IITerminatedSep 25, 2019Allergy ReliefFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1865-2019Class IITerminatedSep 25, 2019Fexofenadine Hydrochrloride Tablets USPFailed Impurities/Degradation SpecificationsAurolife Pharma, LLC · D-1864-2019Class IITerminatedSep 25, 2019Oxcarbazepine Oral SuspensionFailed Impurities/Degradation SpecificattionWest-Ward Columbus Inc · D-1863-2019Class IITerminatedSep 25, 2019Anagrelide CapsulesFailed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.Torrent Pharma Inc. · D-1862-2019Class IITerminatedSep 25, 2019Soothing Sore ReliefSuperpotent Drug: products were found to be contaminated and above specification for lidocaine assay.Ridge Properties, LLC · D-1861-2019Class IITerminatedSep 25, 2019Soothing Sore ReliefSuperpotent Drug: products were found to be contaminated and above specification for lidocaine assay.Ridge Properties, LLC · D-1860-2019Class IITerminatedSep 25, 2019Superior Pain & Itch ReliefSuperpotent Drug: products were found to be contaminated and above specification for lidocaine assay.Ridge Properties, LLC · D-1859-2019Class IITerminatedSep 25, 2019Superior Pain & Itch ReliefSuperpotent Drug: products were found to be contaminated and above specification for lidocaine assay.Ridge Properties, LLC · D-1858-2019Class IITerminatedSep 25, 2019PRE-TATMicrobial Contamination of Non-Sterile Products: products were found to be contaminated and above specification for lidocaine assay.Ridge Properties, LLC · D-1857-2019Class IITerminatedSep 25, 2019PRE-TATMicrobial Contamination of Non-Sterile Products: products were found to be contaminated and above specification for lidocaine assay.Ridge Properties, LLC · D-1856-2019Class ITerminatedSep 18, 2019Milk of Magnesia USPMicrobial Contamination of Non-Sterile Products: product failed bioburden testing for Total Aerobic Microbial Count.Plastikon Healthcare LLC · D-1879-2019Class IITerminatedSep 18, 2019AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mgFailed Stability Specifications.AVKARE Inc. · D-1875-2019Class IITerminatedSep 18, 20195% Acetyl-L-Cysteine Ophthalmic SolutionsLack of Processing Controls:Compounded Solutions in Pharmacy · D-1855-2019Class IITerminatedSep 18, 201910% Acetyl-L-Cysteine Ophthalmic SolutionsLack of Processing Controls:Compounded Solutions in Pharmacy · D-1854-2019Class IITerminatedSep 18, 201920% Acetyl-L-Cysteine Ophthalmic SolutionsLack of Processing Controls:Compounded Solutions in Pharmacy · D-1853-2019Class IITerminatedSep 18, 2019Bacteriostatic Water for InjectionLack of Assurance of SterilityPfizer Inc. · D-1852-2019Class IIITerminatedSep 18, 2019Pramipexole Dihydrochloride Tablets 0.125 mgSubpotent Drug: Out of specification result during stability study in Pramipexole Dihydrochloride Tablets 0.125 mgMacleods Pharma Usa Inc · D-1851-2019Class IITerminatedSep 18, 2019BevacizumabLack of assurance of sterility.Pacifico National, Inc. dba AmEx Pharmacy · D-1850-2019Class IITerminatedSep 18, 2019BevacizumabLack of assurance of sterility.Pacifico National, Inc. dba AmEx Pharmacy · D-1849-2019Class IIITerminatedSep 18, 2019Gatifloxacin Ophthalmic Solution 0.5%Failed Impurities/Degradation Specifications:OOS for unknown impurity.Mylan Pharmaceuticals Inc. · D-1848-2019Class IIITerminatedSep 18, 2019Lamivudine TabletsLabeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for...American Health Packaging · D-1847-2019Class IITerminatedSep 4, 2019VivitrolLabeling: Not Elsewhere Classified. Drug product kit recalled due to 1 inch needles being placed in the 1 1/2 inch needle cardboard sleeve labelled as administration...Alkermes Inc · D-1846-2019Class IITerminatedSep 4, 2019RELPAX (eletriptan HBr) tabletsMicrobial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.Pfizer Inc. · D-1845-2019Class IIITerminatedSep 4, 2019Simvastatin TabletsLabeling; Incorrect or Missing Lot and/or Exp Date; some bottles labeled with lot number 05318054B instead of 05318034BAurobindo Pharma USA Inc. · D-1842-2019Class IIITerminatedSep 4, 2019Eptifibatide InjectionFailed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.Akorn, Inc. · D-1841-2019Class IIITerminatedSep 4, 2019Eptifibatide InjectionShort Fill: fill volume was out of specification at 94 mL (specification: no less than 100 mL) and Failed Impurities/Degradation Specifications: Out of Specification...Akorn, Inc. · D-1840-2019Class IIITerminatedSep 4, 2019Eptifibatide InjectionFailed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.Akorn, Inc. · D-1839-2019Class IITerminatedAug 28, 2019Ketamine 50 mg/5 mL in 0.9% Sodium Chloride Injection for IV or IM UseLack of Assurance of Sterility.SCA Pharmaceuticals, LLC · D-1843-2019Class IITerminatedAug 28, 2019Bexarotene CapsulesFailed Dissolution SpecificationsUpsher Smith Laboratories, Inc. · D-1836-2019